New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
07:17 EDTUTHRUnited Therapeutics price target raised to $150 from $120 at H.C. Wainwright
H.C. Wainwright raised its price target for United Therapeutics shares to $150 citing strong sales and positive prospects following the company's Q2 results. The firm reiterates a Buy rating on the stock.
News For UTHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 12, 2015
10:01 EDTUTHROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Ally Financial (ALLY) upgraded at Evercore ISI... Amarin (AMRN) upgraded to Buy from Neutral at H.C. Wainwright... American Vanguard (AVD) upgraded to Buy from Hold at Topeka... Banc of California (BANC) upgraded to Outperform from Market Perform at Raymond James... CNOOC (CEO) upgraded to Buy from Underperform at BofA/Merrill... Five Below (FIVE) upgraded to Buy from Neutral at Dougherty... Fuel Systems (FSYS) upgraded to Buy from Hold at Lake Street... GNC Holdings (GNC) upgraded at Morgan Stanley... Horizon Technology (HRZN) upgraded to Buy from Hold at Wunderlich... Magnum Hunter (MHR) upgraded to Buy from Neutral at SunTrust... NCI Building (NCS) upgraded to Buy from Neutral at Citigroup... Shore Bancshares (SHBI) upgraded to Outperform from Neutral at Boenning & Scattergood... United Therapeutics (UTHR) upgraded at Argus... Verisk Analytics (VRSK) upgraded to Buy from Hold at Evercore ISI... Windstream (WIN) upgraded to Buy from Neutral at Citigroup... York Water (YORW) upgraded to Neutral from Underperform at Hilliard Lyons.
09:40 EDTUTHRUnited Therapeutics has a conference call hosted by JPMorgan
Subscribe for More Information
08:00 EDTUTHRUnited Therapeutics upgraded at Argus
As previously reported, Argus upgraded United Therapeutics to Buy from Neutral. The firm believes United Therapeutics is entering a new phase of growth following the recent approval of Unituxin in the treatment of neuroblastoma. Argus said the new product offers a diversified revenue stream and recommends buying shares. Price target is $195.
07:56 EDTUTHRUnited Therapeutics upgraded to Buy from Hold at Argus

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use